Glenmark Pharmaceuticals Gets USFDA Approval For Ophthalmic Solution
Glenmark Pharmaceuticals receives final USFDA approval for its generic ophthalmic solution used in treating increased eye pressure caused by glaucoma or other conditions.
Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions.
The final approval by the US Food & Drug Administration is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2%/0.5%, Glenmark said in a statement.
The company's brimonidine tartrate and timolol maleate ophthalmic solution, 0.2%/0.5% has been determined by the USFDA to be bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2%/0.5% of AbbVie, Inc, it added.
The solution will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added.
Combigan ophthalmic solution, 0.2%/0.5% achieved annual sales of approximately $290 million, the company said citing IQVIATM sales data for the 12-month period ended March 2024.
